This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Moretti, R. Articles by Bava, A. Search for Related Content PubMed PubMed Citation Articles by Moretti, R. Articles by Bava, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Statins Social Bookmarking                         What's this?

Rivastigmine in subcortical vascular dementia: A randomized, controlled, open 12-month study in 208 patients

Dipartimento di Fisiologia e Patologia, Università degli Studi di Trieste; Dipartimento di Medicina Clinica e Neurologia, Ambulatorio Disturbi Cognitivi, Università degli Studi di Trieste, Trieste, Italy

Paola Torre, MD

Rodolfo M. Antonello, MD

Giuseppe Cazzato, MD

Dipartimento di Medicina Clinica e Neurologia, Ambulatorio Disturbi Cognitivi, Università degli Studi di Trieste, Trieste, Italy

Antonio Bava, MD

Dipartimento di Fisiologia e Patologia, Università degli Studi di Trieste, Trieste, Italy

Subcortical vascular dementia (VaD) is characterized by executive dysfunction and behavioral problems, reflecting deterioration of the frontal lobe. This study aimed to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effects on the typical symptoms of subcortical VaD. Patients receiving rivastigmine showed a slight improvement in executive functions and in behavior. Side effects in both groups were tolerable and there were no study withdrawals. Moreover, there are no drug interactions with other therapies previously and concomitantly assumed. Improvements in domains that characterize subcortical VaD were observed, indicating that rivastigmine may have provided targeted treatment in areas of the brain that are particularly affected in this patient population.

Key Words: cholinesterase inhibition • behavior • executive function • rivastigmine • vascular dementia

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 18, No. 5, 265-272 (2003)
DOI: 10.1177/153331750301800508


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. R. Farlow Use of Antidementia Agents in Vascular Dementia: Beyond Alzheimer Disease Mayo Clin. Proc., October 1, 2006; 81(10): 1350 - 1358. [Abstract] [Full Text] [PDF]

				J. M. Ellis Cholinesterase Inhibitors in the Treatment of Dementia J Am Osteopath Assoc, March 1, 2005; 105(3): 145 - 158. [Abstract] [Full Text] [PDF]

				L. Pantoni, T. del Ser, A. G. Soglian, S. Amigoni, G. Spadari, D. Binelli, and D. Inzitari Efficacy and Safety of Nimodipine in Subcortical Vascular Dementia: A Randomized Placebo-Controlled Trial Stroke, March 1, 2005; 36(3): 619 - 624. [Abstract] [Full Text] [PDF]

				R. Moretti, P. Torre, R. M. Antonello, T. Cattaruzza, and G. Cazzato Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: A controlled, open 24-month study of 246 patients American Journal of Alzheimer's Disease and Other Dementias, November 1, 2004; 19(6): 333 - 339. [Abstract] [PDF]